Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017 (2017), Article ID 4649191, 11 pages
https://doi.org/10.1155/2017/4649191
Research Article

2D-QSAR and 3D-QSAR Analyses for EGFR Inhibitors

1Shanghai Key Laboratory of Bio-Energy Crops, College of Life Science and Shanghai University High Performance Computing Center, Shanghai University, Shanghai 200444, China
2Department of Oncology, Hainan General Hospital, Haikou, Hainan 570311, China
3Department of Radiology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China
4Changhai Hospital, Second Military Medical University, Shanghai 200433, China
5Department of Life Science, Heze University, Heze, Shandong 274500, China

Correspondence should be addressed to Yuhui Zhang; moc.621@8002gnahc_gnog, Dongshu Du; nc.ude.uhs@udsd, and Bing Niu; moc.361@ycocyhp

Received 6 January 2017; Revised 19 February 2017; Accepted 12 March 2017; Published 29 May 2017

Academic Editor: Vladimir Bajic

Copyright © 2017 Manman Zhao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. Ciardiello and G. Tortora, “EGFR antagonists in cancer treatment,” The New England Journal of Medicine, vol. 358, no. 11, pp. 1160–1174, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. Y. He, B. S. Harrington, and J. D. Hooper, “New crossroads for potential therapeutic intervention in cancer—intersections between CDCP1, EGFR family members and downstream signaling pathways,” Oncoscience, vol. 3, no. 1, pp. 5–8, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Wang, X. Wang, J. Q. Wu et al., “Efficient porcine reproductive and respiratory syndrome virus entry in MARC-145 cells requires EGFR-PI3K-AKT-LIMK1-COFILIN signaling pathway,” Virus Research, vol. 225, pp. 23–32, 2016. View at Publisher · View at Google Scholar
  4. F. Imamura, J. Uchida, Y. Kukita et al., “Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer,” Lung Cancer, vol. 94, pp. 68–73, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Wang, D. Li, and L. Sun, “High levels of EGFR expression in tumor stroma are associated with aggressive clinical features in epithelial ovarian cancer,” OncoTargets and Therapy, vol. 9, pp. 377–386, 2016. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Cho, J. Hur, Y. W. Moon et al., “Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer,” BMC Cancer, vol. 16, no. 1, article 224, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. X. B. Holdman, T. Welte, K. Rajapakshe et al., “Upregulation of EGFR signaling is correlated with tumor stroma remodeling and tumor recurrence in FGFR1-driven breast cancer,” Breast Cancer Research, vol. 17, no. 1, article 141, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Sarkar, “Epidermal growth factor receptor (EGFR) gene amplification in high grade gliomas,” Neurology India, vol. 64, no. 1, pp. 27-28, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Oda, Y. Matsuoka, A. Funahashi, and H. Kitano, “A comprehensive pathway map of epidermal growth factor receptor signaling,” Molecular Systems Biology, vol. 1, p. E1, 2005. View at Google Scholar · View at Scopus
  10. J. C. Baer, A. A. Freeman, E. S. Newlands, A. J. Watson, J. A. Rafferty, and G. P. Margison, “Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells,” British Journal of Cancer, vol. 67, no. 6, pp. 1299–1302, 1993. View at Publisher · View at Google Scholar · View at Scopus
  11. N. Minkovsky and A. Berezov, “BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors,” Current Opinion in Investigational Drugs, vol. 9, no. 12, pp. 1336–1346, 2008. View at Google Scholar · View at Scopus
  12. J. C. Dearden, “The history and development of quantitative structure-activity relationships (QSARs),” International Journal of Quantitative Structure-Property Relationships, vol. 1, no. 1, pp. 1–44, 2016. View at Google Scholar
  13. A. Cherkasov, E. N. Muratov, D. Fourches et al., “QSAR modeling: where have you been? Where are you going to?” Journal of Medicinal Chemistry, vol. 57, no. 12, pp. 4977–5010, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Roy, S. Kar, and R. N. Das, Understanding the Basics of QSAR for Applications in Pharmaceutical Sciences and Risk Assessment, Academic Press, 2015.
  15. D. Gadaleta, G. F. Mangiatordi, M. Catto, A. Carotti, and O. Nicolotti, “Applicability domain for QSAR models: where theory meets reality,” International Journal of Quantitative Structure-Property Relationships, vol. 1, no. 1, pp. 45–63, 2016. View at Publisher · View at Google Scholar
  16. K. Roy, S. Kar, and P. Ambure, “On a simple approach for determining applicability domain of QSAR models,” Chemometrics and Intelligent Laboratory Systems, vol. 145, pp. 22–29, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Lee and M. G. Barron, “Development of 3D-QSAR model for acetylcholinesterase inhibitors using a combination of fingerprint, molecular docking, and structure-based pharmacophore approaches,” Toxicological Sciences, vol. 148, no. 1, pp. 60–70, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Tresadern and D. Bemporad, “Modeling approaches for ligand-based 3D similarity,” Future Medicinal Chemistry, vol. 2, no. 10, pp. 1547–1561, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. K.-C. Chou, “Structural bioinformatics and its impact to biomedical science,” Current Medicinal Chemistry, vol. 11, no. 16, pp. 2105–2134, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. J.-W. Liang, T.-J. Zhang, Z.-J. Li, Z.-X. Chen, X.-L. Yan, and F.-H. Meng, “Predicting potential antitumor targets of Aconitum alkaloids by molecular docking and protein–ligand interaction fingerprint,” Medicinal Chemistry Research, vol. 25, no. 6, pp. 1115–1124, 2016. View at Publisher · View at Google Scholar · View at Scopus
  21. L. Blake and M. E. S. Soliman, “Identification of irreversible protein splicing inhibitors as potential anti-TB drugs: insight from hybrid non-covalent/covalent docking virtual screening and molecular dynamics simulations,” Medicinal Chemistry Research, vol. 23, no. 5, pp. 2312–2323, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Ambure, S. Kar, and K. Roy, “Pharmacophore mapping-based virtual screening followed by molecular docking studies in search of potential acetylcholinesterase inhibitors as anti-Alzheimer's agents,” BioSystems, vol. 116, no. 1, pp. 10–20, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Lv, J. Su, F. Wang, Y. Qi, H. Liu, and Y. Zhang, “Detecting novel hypermethylated genes in Breast cancer benefiting from feature selection,” Computers in Biology and Medicine, vol. 40, no. 2, pp. 159–167, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. F. R. Ajdadi, Y. A. Gilandeh, K. Mollazade, and R. P. Hasanzadeh, “Application of machine vision for classification of soil aggregate size,” Soil and Tillage Research, vol. 162, pp. 8–17, 2016. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Sadeghia, R. Zarkami, K. Sabetraftar, and P. Van Damme, “Application of genetic algorithm and greedy stepwise to select input variables in classification tree models for the prediction of habitat requirements of Azolla filiculoides (Lam.) in Anzali wetland, Iran,” Ecological Modelling, vol. 251, pp. 44–53, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. C. J. C. Burges, “A tutorial on support vector machines for pattern recognition,” Data Mining and Knowledge Discovery, vol. 2, no. 2, pp. 121–167, 1998. View at Publisher · View at Google Scholar · View at Scopus
  27. F. Imani, F. E. Boada, F. S. Lieberman, D. K. Davis, and J. M. Mountz, “Molecular and metabolic pattern classification for detection of brain glioma progression,” European Journal of Radiology, vol. 83, no. 2, pp. e100–e105, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. K. E. Emblem, F. G. Zoellner, B. Tennoe et al., “Predictive modeling in glioma grading from MR perfusion images using support vector machines,” Magnetic Resonance in Medicine, vol. 60, no. 4, pp. 945–952, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. R. D. Cramer, “Topomer CoMFA: a design methodology for rapid lead optimization,” Journal of Medicinal Chemistry, vol. 46, no. 3, pp. 374–388, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. K. Z. Myint and X.-Q. Xie, “Recent advances in fragment-based QSAR and multi-dimensional QSAR methods,” International Journal of Molecular Sciences, vol. 11, no. 10, pp. 3846–3866, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. C. G. Gadhe, “CoMFA vs. Topomer CoMFA, which one is better a case study with 5-lipoxygenase inhibitors,” Journal of the Chosun Natural Science, vol. 4, no. 2, pp. 91–98, 2011. View at Google Scholar
  32. G. W. Rewcastle, W. A. Denny, A. J. Bridges et al., “Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor,” Journal of Medicinal Chemistry, vol. 38, no. 18, pp. 3482–3487, 1995. View at Publisher · View at Google Scholar · View at Scopus
  33. A. M. Thompson, A. J. Bridges, D. W. Fry, A. J. Kraker, and W. A. Denny, “Tyrosine kinase inhibitors. 7. 7-Amino-4-(phenylamino)- and 7-amino-4-[(phenylmethyl)amino]pyrido[4,3-d]pyrimidines: a new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor,” Journal of Medicinal Chemistry, vol. 38, no. 19, pp. 3780–3788, 1995. View at Publisher · View at Google Scholar · View at Scopus
  34. G. W. Rewcastle, A. J. Bridges, D. W. Fry, J. R. Rubin, and W. A. Denny, “Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor,” Journal of Medicinal Chemistry, vol. 40, no. 12, pp. 1820–1826, 1997. View at Publisher · View at Google Scholar · View at Scopus
  35. A. M. Thompson, D. K. Murray, W. L. Elliott et al., “Tyrosine kinase inhibitors. 13. Structure—activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor,” Journal of Medicinal Chemistry, vol. 40, no. 24, pp. 3915–3925, 1997. View at Publisher · View at Google Scholar · View at Scopus
  36. A. J. Bridges, H. Zhou, D. R. Cody et al., “Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor,” Journal of Medicinal Chemistry, vol. 39, no. 1, pp. 267–276, 1996. View at Publisher · View at Google Scholar · View at Scopus
  37. G. W. Rewcastle, B. D. Palmer, A. M. Thompson et al., “Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor,” Journal of Medicinal Chemistry, vol. 39, no. 9, pp. 1823–1835, 1996. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Li, C. Guo, H. Zhao, Y. Tang, and M. Lan, “Synthesis and biological evaluation of 4-[3-chloro-4-(3-fluorobenzyloxy) anilino]-6-(3-substituted-phenoxy)pyrimidines as dual EGFR/ErbB-2 kinase inhibitors,” Bioorganic and Medicinal Chemistry, vol. 20, no. 2, pp. 877–885, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. A. G. Waterson, K. G. Petrov, K. R. Hornberger et al., “Synthesis and evaluation of aniline headgroups for alkynyl thienopyrimidine dual EGFR/ErbB-2 kinase inhibitors,” Bioorganic and Medicinal Chemistry Letters, vol. 19, no. 5, pp. 1332–1336, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. N. Suzuki, T. Shiota, F. Watanabe et al., “Synthesis and evaluation of novel pyrimidine-based dual EGFR/Her-2 inhibitors,” Bioorganic and Medicinal Chemistry Letters, vol. 21, no. 6, pp. 1601–1606, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. N. Suzuki, T. Shiota, F. Watanabe et al., “Discovery of novel 5-alkynyl-4-anilinopyrimidines as potent, orally active dual inhibitors of EGFR and Her-2 tyrosine kinases,” Bioorganic and Medicinal Chemistry Letters, vol. 22, no. 1, pp. 456–460, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. J. J. Irwin, “Software review: ChemOffice 2005 Pro by Cambridgesoft,” Journal of Chemical Information and Modeling, vol. 45, no. 5, pp. 1468-1469, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Varma and R. Simon, “Bias in error estimation when using cross-validation for model selection,” BMC Bioinformatics, vol. 7, supplement 5, pp. 91–98, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. L. Wang, H. Shen, B. Li, and D. Hu, “Classification of schizophrenic patients and healthy controls using multiple spatially independent components of structural MRI data,” Frontiers of Electrical and Electronic Engineering in China, vol. 6, no. 2, pp. 353–362, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. Y. P. Zhang, N. Sussman, G. Klopman, and H. S. Rosenkranz, “Development of methods to ascertain the predictivity and consistency of SAR models: application to the U.S. National toxicology program rodent carcinogenicity bioassays,” Quantitative Structure-Activity Relationships, vol. 16, no. 4, pp. 290–295, 1997. View at Publisher · View at Google Scholar · View at Scopus
  46. K. Roy, R. N. Das, P. Ambure, and R. B. Aher, “Be aware of error measures. Further studies on validation of predictive QSAR models,” Chemometrics and Intelligent Laboratory Systems, vol. 152, pp. 18–33, 2016. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Yu, J. Yuan, J. Shi et al., “HQSAR and topomer CoMFA for predicting melanocortin-4 receptor binding affinities of trans-4-(4-chlorophenyl) pyrrolidine-3-carboxamides,” Chemometrics and Intelligent Laboratory Systems, vol. 146, pp. 34–41, 2015. View at Publisher · View at Google Scholar · View at Scopus
  48. S. Kumar and M. Tiwari, “Topomer-CoMFA-based predictive modelling on 2,3-diaryl-substituted-1,3-thiazolidin-4-ones as non-nucleoside reverse transcriptase inhibitors,” Medicinal Chemistry Research, vol. 24, no. 1, pp. 245–257, 2015. View at Publisher · View at Google Scholar · View at Scopus
  49. Y. Tian, Y. Shen, X. Zhang et al., “Design some new type-I c-met inhibitors based on molecular docking and topomer comfa research,” Molecular Informatics, vol. 33, no. 8, pp. 536–543, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. G. Tresadern, J.-M. Cid, and A. A. Trabanco, “QSAR design of triazolopyridine mGlu2 receptor positive allosteric modulators,” Journal of Molecular Graphics and Modelling, vol. 53, pp. 82–91, 2014. View at Publisher · View at Google Scholar · View at Scopus
  51. H. Tang, L. Yang, J. Li, and J. Chen, “Molecular modelling studies of 3,5-dipyridyl-1,2,4-triazole derivatives as xanthine oxidoreductase inhibitors using 3D-QSAR, Topomer CoMFA, molecular docking and molecular dynamic simulations,” Journal of the Taiwan Institute of Chemical Engineers, vol. 68, pp. 64–73, 2016. View at Publisher · View at Google Scholar
  52. S. D. Joshi, U. A. More, D. Koli, M. S. Kulkarni, M. N. Nadagouda, and T. M. Aminabhavi, “Synthesis, evaluation and in silico molecular modeling of pyrroyl-1,3,4-thiadiazole inhibitors of InhA,” Bioorganic Chemistry, vol. 59, pp. 151–167, 2015. View at Publisher · View at Google Scholar · View at Scopus
  53. J. Stamos, M. X. Sliwkowski, and C. Eigenbrot, “Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor,” Journal of Biological Chemistry, vol. 277, no. 48, pp. 46265–46272, 2002. View at Publisher · View at Google Scholar · View at Scopus
  54. J. Miao and L. Niu, “A survey on feature selection,” Procedia Computer Science, vol. 91, pp. 919–926, 2016. View at Publisher · View at Google Scholar
  55. V. Bolón-Canedo, N. Sánchez-Maroño, and A. Alonso-Betanzos, “Feature selection for high-dimensional data,” Progress in Artificial Intelligence, vol. 5, no. 2, pp. 65–75, 2016. View at Publisher · View at Google Scholar
  56. B. Niu, Q. Su, X. Yuan, W. Lu, and J. Ding, “QSAR study on 5-lipoxygenase inhibitors based on support vector machine,” Medicinal Chemistry, vol. 8, no. 6, pp. 1108–1116, 2012. View at Publisher · View at Google Scholar · View at Scopus
  57. W. Ding, M. Sun, S. Luo et al., “A 3D QSAR study of betulinic acid derivatives as anti-tumor agents using topomer CoMFA: model building studies and experimental verification,” Molecules, vol. 18, no. 9, pp. 10228–10241, 2013. View at Publisher · View at Google Scholar · View at Scopus
  58. Y. Xiang, J. Song, and Z. Zhang, “Topomer CoMFA and virtual screening studies of azaindole class renin inhibitors,” Combinatorial Chemistry and High Throughput Screening, vol. 17, no. 5, pp. 458–472, 2014. View at Publisher · View at Google Scholar · View at Scopus
  59. K. Roy, P. Ambure, and R. B. Aher, “How important is to detect systematic error in predictions and understand statistical applicability domain of QSAR models?” Chemometrics and Intelligent Laboratory Systems, vol. 162, pp. 44–54, 2017. View at Publisher · View at Google Scholar
  60. T. A. Farghaly, H. M. E. Hassaneen, and H. S. A. Elzahabi, “Eco-friendly synthesis and 2D-QSAR study of novel pyrazolines as potential anticolon cancer agents,” Medicinal Chemistry Research, vol. 24, no. 2, pp. 652–668, 2015. View at Publisher · View at Google Scholar · View at Scopus
  61. M. C. Sharma, “2D QSAR studies of the inhibitory activity of a series of substituted purine derivatives against c-Src tyrosine kinase,” Journal of Taibah University for Science, vol. 10, no. 4, pp. 563–570, 2016. View at Publisher · View at Google Scholar
  62. M. C. Sharma, S. Sharma, and K. Bhadoriya, “QSAR studies on pyrazole-4-carboxamide derivatives as Aurora A kinase inhibitors,” Journal of Taibah University for Science, vol. 10, no. 1, pp. 107–114, 2016. View at Publisher · View at Google Scholar